| 1 Adverse effects |
1 |
71 |
Risk Ratio (M‐H, Fixed, 95% CI) |
4.86 [0.24, 97.86] |
| 2 Short‐term improvement in CTS symptom severity (Levine) (3 months or less) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 2.1 At end of 4 weeks treatment |
1 |
71 |
Mean Difference (IV, Fixed, 95% CI) |
0.21 [‐0.02, 0.44] |
| 2.2 At 8 weeks post‐treatment |
1 |
71 |
Mean Difference (IV, Fixed, 95% CI) |
0.25 [‐0.03, 0.53] |
| 3 Short‐term improvement in functional status (Levine) (3 months or less) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 3.1 At the end of 4 weeks treatment |
1 |
71 |
Mean Difference (IV, Fixed, 95% CI) |
0.12 [‐0.05, 0.29] |
| 3.2 At 8 weeks post‐treatment |
1 |
71 |
Mean Difference (IV, Fixed, 95% CI) |
0.12 [‐0.06, 0.30] |
| 4 Short‐term improvement in median nerve motor distal latency (ms) (3 months or less) |
2 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 4.1 At the end of 4 weeks treatment |
1 |
71 |
Mean Difference (IV, Random, 95% CI) |
0.14 [‐0.18, 0.46] |
| 4.2 At the end of 6 weeks treatment |
1 |
43 |
Mean Difference (IV, Random, 95% CI) |
0.29 [‐0.34, 0.92] |
| 4.3 At 8 weeks post‐treatment |
1 |
71 |
Mean Difference (IV, Random, 95% CI) |
0.27 [‐0.03, 0.57] |
| 5 Short‐term improvement in median nerve sensory distal latency (ms) (3 months or less) |
2 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 5.1 At the end of 4 weeks treatment |
1 |
71 |
Mean Difference (IV, Random, 95% CI) |
0.33 [‐0.06, 0.72] |
| 5.2 At the end of 6 weeks treatment |
1 |
43 |
Mean Difference (IV, Random, 95% CI) |
0.20 [‐0.18, 0.58] |
| 5.3 At 8 weeks post‐treatment |
1 |
71 |
Mean Difference (IV, Random, 95% CI) |
0.56 [0.28, 0.84] |
| 6 Short‐term improvement in motor nerve conduction velocity (m/s) (3 months or less) |
2 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 6.1 At the end of 4 weeks treatment |
1 |
71 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.14 [‐3.84, 3.56] |
| 6.2 At the end of 6 weeks treatment |
1 |
43 |
Mean Difference (IV, Fixed, 95% CI) |
2.07 [‐0.74, 4.88] |
| 6.3 At 8 weeks post‐treatment |
1 |
71 |
Mean Difference (IV, Fixed, 95% CI) |
‐3.28 [‐6.35, ‐0.21] |
| 7 Short‐term improvement in sensory nerve conduction velocity (m/s) (3 months or less) |
2 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 7.1 At the end of 4 weeks treatment |
1 |
71 |
Mean Difference (IV, Fixed, 95% CI) |
0.65 [‐3.02, 4.32] |
| 7.2 At the end of 6 weeks treatment |
1 |
43 |
Mean Difference (IV, Fixed, 95% CI) |
‐2.92 [‐9.34, 3.50] |
| 7.3 At 8 weeks post‐treatment |
1 |
71 |
Mean Difference (IV, Fixed, 95% CI) |
‐3.95 [‐7.60, ‐0.30] |
